Prenosis’ Sepsis ImmunoScore™, Innovative Sepsis Diagnostic Technology, Now Supported by Enhanced Documentation and Reimbursement Pathway
CHICAGO, IL – October 1, 2025 – The Centers for Medicare & Medicaid Services (CMS) has officially released the FY 2026 ICD-10-CM Diagnosis Code Files and ICD-10-PCS Procedure Code Files, marking a significant milestone for sepsis care documentation. The new coding structure, available on CMS’ website, facilitates documentation of AI sepsis diagnostic technologies, including Sepsis ImmunoScore.
Effective October 1, 2025, hospitals nationwide can begin utilizing the newly approved code XXEZXCB: Measurement of Infection, Computer-aided Triage and Notification, New Technology Group 11 to document the clinical use of Prenosis’ Sepsis ImmunoScore. This code represents a crucial advancement in the standardization and recognition of computer-aided sepsis diagnostic technologies within the healthcare system.
The establishment of this specific ICD-10-PCS code serves dual purposes for healthcare institutions. It enables accurate documentation of Sepsis ImmunoScore utilization, ensuring proper tracking and reporting of this diagnostic tool’s implementation. Additionally, the code designation represents a necessary prerequisite step for New Technology Add-on Payment (NTAP) submission processes.
“This official code recognition validates the clinical significance of advanced sepsis diagnostics and provides hospitals with the documentation framework needed to support improved patient outcomes,” said Robin Carver, SVP of Commercialization for Prenosis. “The ability to properly code and track these technologies is essential for both clinical quality measurement and reimbursement optimization.”
Healthcare organizations implementing Sepsis ImmunoScore can now seamlessly integrate this technology into their existing documentation workflows while building the foundation for future NTAP applications. This development underscores the healthcare industry’s commitment to adopting evidence-based diagnostic innovations that enhance sepsis detection and patient care.
About Prenosis, Inc.
Prenosis, Inc. is a biology-based technology company redefining the standard of care for critical conditions. We believe healthcare should not follow a one-size-fits-all model. Instead, our mission is to tailor healthcare to each patient’s biology through the creation and delivery of integrated diagnostics and therapeutics. We use deep data and AI to build tools that augment clinical diagnosis of critical conditions based on each patient’s unique biological profile. Unlike other AI-driven diagnostics, we go further by developing therapies that help providers deliver personalized care. Our Immunix™ platform powers the development of a variety of AI-based diagnostics, including Sepsis ImmunoScore™, the first FDA-authorized AI diagnostic tool for sepsis. At Prenosis, we see people differently. For more information, visit us at prenosis.yourstagedsite.com/ or find us on LinkedIn.